{"title":"Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India.","authors":"Abhishek Das, Kothapally Saiteja, Parag K Shah, Subramaniam Prema, Venkatapathy Narendran","doi":"10.5409/wjcp.v14.i3.103732","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intra-arterial chemotherapy (IAC) has become a first-line standard treatment for retinoblastoma (RB). However, studies describing its adverse events are sparse, especially from the developing world. Our study described the outcomes and adverse events from a single center in South India.</p><p><strong>Aim: </strong>To describe the challenges, treatment outcomes, and complications of selective IAC for RB in Indian eyes.</p><p><strong>Methods: </strong>This study was a single center, retrospective study that included 17 patients with RB who underwent IAC using melphalan (5/7.5 mg) and topotecan (1/2 mg) (<i>n</i> = 12) or melphalan (5 mg) alone (<i>n</i> = 3) or triple therapy that included carboplatin (30 mg) along with these drugs (<i>n</i> = 2) between January 2018 and December 2023. In all, 17 IAC procedures were performed using selective ophthalmic artery cannulation. Treatment outcomes were evaluated in terms of tumor control, vitreous and subretinal seed control, complications, and globe salvage rates.</p><p><strong>Results: </strong>Out of the 17 patients, 11 were diagnosed with unilateral RB and 6 were diagnosed with bilateral RB. The mean age at the time of diagnosis was 19.8 months. The mean interval between the first symptom and presentation was 6.5 months. IAC was employed as the primary (<i>n</i> = 9) or secondary (<i>n</i> = 8) modality of treatment. Each eye received a mean of 1.5 IAC sessions (median: 1 session; range: 1-3 sessions). Eyes were classified according to the international classification of RB as group B (<i>n</i> = 5), group C (<i>n</i> = 1), group D (<i>n</i> = 4), and group E (<i>n</i> = 7). Following IAC, complete regression of the main tumor was seen in 15 eyes (88%) and partial regression in 2 eyes (12%). Globe salvage was achieved in 15 eyes (88%). Adverse effects included vitreous hemorrhage (<i>n</i> = 3), rhegmatogenous retinal detachment (<i>n</i> = 2), choroidal ischemia (<i>n</i> = 1), isolated subretinal hemorrhage (<i>n</i> = 2), retinal pigment epithelium degeneration (<i>n</i> = 2), forehead pigmentation (<i>n</i> = 1), third nerve palsy with complete ptosis (<i>n</i> = 1), and 30-degree exotropia (<i>n</i> = 1). The mean follow-up period was 28.6 months (median: 24 months, range: 1-72 months).</p><p><strong>Conclusion: </strong>IAC is an effective way to control RB and globe preservation. In the Indian context we encountered many challenges highlighting the importance of case selection. Further studies in India are required to thoroughly understand IAC as a treatment for RB.</p>","PeriodicalId":75338,"journal":{"name":"World journal of clinical pediatrics","volume":"14 3","pages":"103732"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304904/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5409/wjcp.v14.i3.103732","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intra-arterial chemotherapy (IAC) has become a first-line standard treatment for retinoblastoma (RB). However, studies describing its adverse events are sparse, especially from the developing world. Our study described the outcomes and adverse events from a single center in South India.
Aim: To describe the challenges, treatment outcomes, and complications of selective IAC for RB in Indian eyes.
Methods: This study was a single center, retrospective study that included 17 patients with RB who underwent IAC using melphalan (5/7.5 mg) and topotecan (1/2 mg) (n = 12) or melphalan (5 mg) alone (n = 3) or triple therapy that included carboplatin (30 mg) along with these drugs (n = 2) between January 2018 and December 2023. In all, 17 IAC procedures were performed using selective ophthalmic artery cannulation. Treatment outcomes were evaluated in terms of tumor control, vitreous and subretinal seed control, complications, and globe salvage rates.
Results: Out of the 17 patients, 11 were diagnosed with unilateral RB and 6 were diagnosed with bilateral RB. The mean age at the time of diagnosis was 19.8 months. The mean interval between the first symptom and presentation was 6.5 months. IAC was employed as the primary (n = 9) or secondary (n = 8) modality of treatment. Each eye received a mean of 1.5 IAC sessions (median: 1 session; range: 1-3 sessions). Eyes were classified according to the international classification of RB as group B (n = 5), group C (n = 1), group D (n = 4), and group E (n = 7). Following IAC, complete regression of the main tumor was seen in 15 eyes (88%) and partial regression in 2 eyes (12%). Globe salvage was achieved in 15 eyes (88%). Adverse effects included vitreous hemorrhage (n = 3), rhegmatogenous retinal detachment (n = 2), choroidal ischemia (n = 1), isolated subretinal hemorrhage (n = 2), retinal pigment epithelium degeneration (n = 2), forehead pigmentation (n = 1), third nerve palsy with complete ptosis (n = 1), and 30-degree exotropia (n = 1). The mean follow-up period was 28.6 months (median: 24 months, range: 1-72 months).
Conclusion: IAC is an effective way to control RB and globe preservation. In the Indian context we encountered many challenges highlighting the importance of case selection. Further studies in India are required to thoroughly understand IAC as a treatment for RB.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
